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ABSTRACT: The total synthesis of hyacinthacines B3, B4, and B5, purported 
hyacinthacine B7, 7-epi- hyacinthacine B7, and 7a-epi- hyacinthacine B3 from a common 
anti-1,2-amino alcohol precursor is described. These syntheses confirmed that the 
proposed structures and absolute configurations of hyacinthacines B3, B4, and B5 were 
correct and disclosed that the proposed structure of hyacinthacine B7 was incorrect. Our 
synthetic and spectroscopic studies suggest that the natural hyacinthacines B5 and B7 are 








The hyacinthacine alkaloids are a relatively recent addition to the group of 
polyhydroxylated 3-hydroxymethylpyrrolizidine natural products.1,2 These alkaloids, 
along with the other related polyhydroxylated pyrrolidine, piperidine, indolizidine and 
nortropane alkaloids, often have specific glycosidase inhibitory activities. Some of 
these, and their more drug like derivatives, have been identified as potential antiviral, 
anticancer, antidiabetic and antiobesity drugs.1 Nineteen hyacinthacine alkaloids of 
general structure 1 (Fig. 1) have been isolated. The first came from the Hyacinthaceae 
family of plants (Hyacinthoides nonscripta, the common bluebell)3a while the others 
have been isolated from the bulb extracts of Muscari armeniacum,3b Scilla 
campanulata,3a S. sibirica,3c and S. sociali.3d Related alkaloids, having extended side 
chains at C-5, have been isolated from S. peruviana.3e In general these alkaloids show 
relatively weak glycosidase inhibitory activities with the best only having moderate 
activities (IC50 ca 5−20 µM) against α- and β-glucosidases, β-galactosidases, and 
amylglucosidases.3a−d These alkaloids have been classified as hyacinthacines A1−7, 
B1−7, and C1−5 based on their total number of hydroxy and hydroxymethyl groups in 
the ring B.3a−d The structures and relative configurations of these natural products 
have been assigned based solely on NMR and MS spectroscopic analysis with the 
only X-ray crystalographic study made on synthetic material.4 The synthesis of these 
alkaloids has confirmed many of these structures and allowed assignment of their 
absolute configurations. Most of these syntheses have involved starting materials 
from Nature’s chiral pool (carbohydrates,5a−o amino acids,5p−r and diethyl tartrate5s-u). 
Others include an enzymatic resolution step followed by diastereoselective 
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synthesis,4,6 a [2+2]-cycloaddition approach using a chiral auxiliary7 and a 
chemoenzymatic synthesis using an aldolase.8 The synthesis of epimers9 and a 
racemic synthesis have also been reported.10 Synthetic studies have revealed that the 
proposed structures of hyacinthacines B7,11 C3,5q and C59f are incorrect. Thus new 
methods for the synthesis of these compounds is important not only to confirm their 
structures but also to provide analogues for structure-activity relationship studies. In 
an earlier communication we reported the development of a new synthetic strategy 
towards these alkaloids and the first synthesis of hyacinthacine B3 2 from (2S)-4-
penten-2-ol.11 This synthesis confirmed the structural identity and the absolute 
configuration of this alkaloid. The synthesis of the proposed structure of 
hyacinthacine B7 3, the C-5 epimer of hyacinthacine B3, was also described starting 
from (2R)-4-penten-2-ol, which indicated that the structure proposed for the natural 
product was incorrect.11 We report here the full details of the synthesis of these 
compounds and the synthesis of hyacinthacine B5 5 and the analogue 7-epi- 
hyacinthacine B7  6, a possible correct structure for natural hyacinthacine B7, from 
(2S)-4-penten-2-ol as a common chiral synthetic precursor. Two side products from 
the synthesis of 5 were hyacinthacine B4 4 and 7a-epi- hyacinthacine B3. These 
syntheses confirmed the structures and absolute configurations of natural 
hyancinthacines B3, B4, and B5. From further analysis of their NMR spectroscopic 
data, and those of the other epimeric compounds that we have prepared, we propose 
that the structure of naturally occuring hyacinthacine B7 has been missassigned and is 
actually hyacinthacine B5.. Unfortunately, the unavailabilty of these natural products 
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Figure 1. General structure of the hyacinthacine alkaloids and target molecules 
 
RESULTS AND DISCUSSION 
Synthesis of hyacinthacine B3 
Our retrosynthetic analysis of hyacinthacines B3, B5, B7, and 7-epi-hyacinthacine B7 
suggested that the 1,2-anti-amino alcohol 7, which we used earlier as a precursor for the 
total synthesis of hyacinthacine B3 2,11 could serve as a useful common intermediate to 
the total synthesis of all four target compounds (Scheme 1). We anticipated that the 
configurations at C-2 and/or C-4 in 7 could be sequentially inverted to allow ready access 
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to each of these related synthetic targets. In our earlier synthesis of hyacinthacine B3 2 the 
α-hydroxy aldehyde 8, or its cyclic acetal derivative, was prepared by an asymmetric 
dihydroxylation (ADH) reaction of the vinyl sulfone 11 (Scheme 1).11,12 This aldehyde 
was not isolated but treated with a mixture of β-styrenyl boronic acid 9 and the chiral 
allylic amine 1013 under boronic acid Mannich reaction conditions14 to give the 1,2-anti-
amino alcohol 7.11 However we found that this method was not readily amenable to the 
scale up synthesis of 7 that was required here and the best overall yield of 7 that we could 
obtain on a several hundred milligram scale was 37% for the two steps. We thus devised 
an alternative synthesis of the aldehyde 8 from the alkene 12. 
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The ADH reactions of the alkene 12 using AD-mix-β ((1 mol % (DHQD)2PHAL, t-
BuOH/H2O (1:1), methanesulfonamide (1 mol equiv) at rt or at 3 oC over 3 d gave the 
desired diol 13, however in poor yields (15% and 24%, respectively) with no 
diastereoselectivity (dr = 1:1) (Scheme 2). The dr of 13 was conveniently determined by 
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1H NMR analysis, the desired 2R diastereomer showed a resolved doublet resonance at δ 
4.54 (J 11.5 Hz, OCHHPMP) while the undesired 2S diastereomer had a resolved doublet 
resonance at δ 4.57 (J 11.5 Hz, OCHHPMP). The yields and diastereoselectivities were 
enhanced significantly when DHQD-IND or (DHQD)2PYR were used instead of 
(DHQD)2PHAL as the chiral ligand at 3 oC over 3 d (65% yield, dr = 3:1 and 61% yield 
and dr = 4:1, respectively).15 However, the yield of the diol 13 was nearly quantitative 
(99%) when the latter reaction was run at 3 oC for 3 d in t-BuOH/H2O (1:2) without 
compromising the diastereoselectivity (dr = 4:1). While these diastereomeric diols could 
be separated by careful column chromatography it proved more convenient to take the 
diastereomeric mixture through to the 1,2-anti-amino alcohol 7 and purify the reaction 
product mixture at this stage. Thus the diol 13 (dr = 4:1) was oxidized with TEMPO and 
sodium hypochlorite in a two phase system (sat. aqueous NaHCO3/CH2Cl2) at 0 oC for 30 
min16 to give a product mixture which we assumed was a mixture of hemiacetals 14 since 
NMR analysis showed no aldehyde signals (Scheme 2). The unpurified material was then 
immediately treated with β-styrenyl boronic acid 9 and the chiral allylic amine 10 in 
CH2Cl2 solution at rt for 2 d.14 The crude reaction mixture was purified by column 
chromatography to give the 1,2-anti-amino alcohol 7 in 73% overall yield for the two 
steps as essentially a single diastereomer (dr = 95:5, Scheme 2). The minor diastereomer 
of 7, that could possibly arise from the reaction of 2S-13 with 9 and 10, could not be 
isolated from the above mentioned column chromatography. The 1H and 13C NMR 
spectra of 7 matched closely with those of compound 7 that we prepared earlier starting 
from the vinyl sulfone 11.11 
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In order to prepare the A-ring of hyacinthacine B3 2, via a ring closing metathesis (RCM) 
reaction of the diene 7, the 1,2-amino alcohol moiety of 7, which may deactivate the 
ruthenium catalyst by coordination, was protected first as its oxazolidinone derivative 15 
(66% yield) by treatment with triphosgene/Et3N (Scheme 3). 1H NMR analysis of 15, 
showed J4,5 = 8.1 Hz, the magnitude of this vicinal coupling constant was consistent with 
the 4,5-cis relative stereochemistry of 15,14c this assignment was further established from 
the NOESY correlation between H4 and H5 (Scheme 3). These results also confirmed the 
anti-configuration assigned to the 1,2-amino alcohol moiety in 7 which was expected  
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based upon mechanistic considerations and literature precedent (see intermediate A in 
Scheme 2)14 
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A ruthenium catalyzed RCM reaction of 15, using 5 mol% Grubbs’ second generation 
catalyst, gave the pyrrolo[1,2-c]oxazol-3-one 16 in 90% yield. Based on our previous 
work,17,18a and that of Parsons,18b,c we expected that the syn-dihydroxylation (DH) of 16 
would furnished the corresponding 6α,7α-diol 17 with the desired configuration for the 
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synthesis of the target alkaloid. In the event, the Os(VIII)-catalysed syn-DH of 16 
provided the desired diol 17 as a single diastereoisomer in 96% yield. Earlier we 
explained this high level of diastereoselectivity based on stereoelectronic effects and an 
examination of the HOMO of 16 about the alkene moiety.11 The non-bonding orbital 
bearing the electron pair on the N-atom overlaps more effectively with the π-system of 
the alkene moiety on the concave face (α-face) of the molecule making this more 
hindered face more prone to dihydroxylation.18b,c The β-benzyloxymethyl substituent at 
C-5 also contributes partially to the diastereofacial selectivity, since the DH of a similar 
substrate which lacked this C-5 substituent was less diastereoselective.19 Importantly, the 
pyrrolo[1,2-c]oxazol-3-one 16 has allowed us to secure the desired 2,3-diol configuration 
of the alkaloid 2, on essentially a trans-2,5-disubstituted-2,5-dihydropyrrole A-ring 
precursor, that would otherwise be expected to be problematic. Compound 17 was readily 
converted to the amino diol 20 (Scheme 3) by three efficient consecutive reactions: (i) a 
bis-O-benzylation reaction to give 18 (100% yield); (ii) O-PMB deprotection of 18 with 
DDQ under aqueous conditions11 to give 19 (89% yield); and (iii) base hydrolysis of 19 
under microwave heating (96% yield of 20). Treatment of 20 with 1.05 equivalents of 
MsCl4 under basic conditions (Et3N) at 0 oC gave the pyrrolizidine 21 in 100% yield. 
Debenzylation of 21 under hydrogenolysis conditions using PdCl2/H217 gave 
hyacinthacine B3 2 in 68% yield after purification and neutralization by basic ion-
exchange chromatography (Scheme 3). The overall yield of 2 from 12 was 24%. The 1H 
and 13C NMR spectral data of this compound matched very closely to those reported in 
the literature (see SI).3b The configuration assigned to this compound was confirmed by 
NOESY NMR studies (see SI). The optical rotation of this compound ([α] 23D
 +10.8 (c 
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0.33, H2O)) was larger in magnitude but of the same sign to that reported (lit.3b [α]D +3.3 
(c 0.31, H2O)). Thus this synthesis confirms the proposed structure and absolute 
configuration of hyacinthacine B3 2. 
 
Synthesis of the purported structure of hyacinthacine B7 and 7-epi-hyacinthacine B7 
The proposed structure of hyacinthacine B7 (3) was prepared from 19 according to 
Scheme 4 (a). The unprotected secondary alcohol of 19 was converted to the 4-
nitrobenzoate derivative 22, with inversion of configuration, under Mitsunobu reaction 
conditions.20 Base hydrolysis of both the ester and oxazolidinone moieties of 22 was 
achieved under microwave heating conditions which furnished the amino diol 23 in 97% 
yield. This compound was identical to the compound we prepared in our earlier synthesis 
of 23 starting from (2R)-4-penten-2-ol.11 Treatment of 23 with 1.05 equivalents of MsCl 
under basic conditions (Et3N) at 0 oC gave the pyrrolizidine 24 in 77% yield after 
purification by column chromatography. Debenzylation of 24 under hydrogenolysis 
conditions using PdCl2/H214 gave the purported structure of hyacinthacine B7 (3) in 68% 
yield after purification and neutralization by basic ion-exchange chromatography 
(Scheme 4 (a)). Of significant concern was that the 1H and 13C NMR spectral data of 
synthetic 3 did not match with those reported for hyacinthacine B7 (see SI).3d Further its 
specific rotation [α] 24D
 + 31.2 (c 0.20, H2O) was significantly different and of the opposite 
sign to that of the natural product ([α] D
 − 4.4 (c 0.20, H2O).3d NOESY NMR analysis of 
our synthetic compound clearly indicated that it had the correct relative configuration, 
significantly, a NOESY correlation was observed between H-5 and H-7 in 3 (See ref 11 
for details) but this was not reported for hyacinthacine B7 in the original isolation paper. 
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Scheme 4. (a) Synthesis of the purported structure of hyacinthacine B7 (3) and (b) 7-epi-
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Unfortunately a sample of natural hyacinthacine B7 was no longer available from the 
authors for comparison with our synthetic product.11 However, as communicate earlier, a 
GC-MS analysis of the crude extract of the same Scilla socialis plants used in the original 
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isolation paper showed no hyacinthacine corresponding to the retention time of 10.71 min 
for the tetra-TMS derivative of 3 (base ion at 388 amu (100%)) while four hyacinthacines 
in the S. socialis extract showed the same fragmentation pattern suggesting they were 
epimers of 3.11 This analysis strongly suggested that 3 does not occur in that plant 
although epimers of 3 clearly do.  
This information, and the differences in NOESY correlations between H-5 and H-7 in 
synthetic 3 and natural hyacinthacine B7, suggested to us that the natural product might 
be 7-epi-hyacinthacine B7 (6), since the other possible A-ring epimer, hyacinthacine B5 
(5), had already been reported as a natural product.3c To examine this possibility 
compound 6 was prepared from the pyrrolizidine 24 according to Scheme 4 (b). Thus the 
unprotected secondary alcohol in pyrrolizidine 24 was oxidized under Swern oxidation 
conditions21 to give the ketone 25 in 63% yield. A diastereoselective reduction of this 
ketone with L-selectride from the less hindered convex face (β-face) of the pyrrolizidine 
structure gave the alcohol 26, which was epimeric at C-7 with its precursor 24. 
Debenzylation of 26 over PdCl2/H217 gave 7-epi-hyacinthacine B7 (6) in 84% yield after 
purification and neutralization by basic ion-exchange chromatography (Scheme 4 (b)). 
While the 1H and 13C NMR spectroscopic data for this compound were a closer match to 
those of hyacinthacine B7 than to those of synthetic 3, they were nonetheless not identical 
(see SI).  
 
Synthesis of hyacinthacines B4 and B5 and 7a-epi-hyacinthacine B3 
While the above synthetic strategies readily provided the three desired target molecules, 
our synthesis of hyacinthacine B5 (5) did not proceeded as efficiently as planned. Our 
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plan was to oxidize the secondary alcohol of 21 to the corresponding C-7 ketone and then 
convert this to the C-7 α-carbinol 28 by a diastereoselective reduction with L-selectride 
using the conditions we had successfully employed in Scheme 4 (b). Compound 28 
would then be de-O-benzylated to give hyacinthacine B5 (5). Surprizingly, the Swern 
oxidation of alcohol 21 gave the unexpected lactam-carboxylic acid 27 as the major 
oxidation product along with an inseparable mixture that comprised three other products 
from 1H NMR analysis (Scheme 5 (a)). MS analysis of this mixture indicated that one of 
the components of this mixture might have been the desired ketone. The yield of 27 was 
16% when the reaction mixture was held at −78 oC for 1 h and 38% when the oxidation 
mixture was treated with Et3N at −78 oC and then warmed to rt for 1 h. When the crude 
oxidation product mixture from the former oxidation reaction conditions (−78 oC for 1 h) 
was treated with L-selectride, and then separated by column chromatography, four new 
compounds could be isolated, all in low yields, and identified. One product was the 
lactam-alcohol 31 (8% yield), while the diastereomeric alcohols 28 (7%), and 30 (4%) 
and the ketone 29 (7%) comprised the other three products (Scheme 5 (b)). The 
configurations of the products 28, 29 and 30 were determined from NOESY NMR 
experiments and their structures were further supported by their conversions to, 
hyacinthacine B5 (5) via hydrogenolysis, hyacinthacine B4 (4) via a diastereoselective L-
selectride reduction to alcohol 32 and then hydrogenolysis, and 7a-epi-hyacinthacine B3 
33 via hydrogenolysis, respectively (Scheme 5 (c)). The 1H and 13C NMR spectroscopic 
data of synthetic compounds 4 and 5 matched very closely to those reported for these 
individual natural products, respectively (see SI).3c The configurations assigned to these 
synthetic compounds were confirmed by NOESY NMR studies (see SI). The optical 
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rotation of 5 ([α] 25D - 21.6 
o, c 0.08, H2O) matched well with that of natural hyacinthacine 
B5 ([α] D - 25.4 
o, c 0.26, H2O)3c as did that of 4 ([α] 25D - 7.7 
o, c 0.18, H2O) and natural 
hyacinthacine B4 ([α] D  - 6.7 
o, c 1.19, H2O).3c Thus these syntheses confirm the proposed 





















Scheme 5. Synthesis of hyacinthacine B4 4, hyacinthacine B5 5, and 7a-epi-
hyancinthacine B3 33 
1. PdCl2, H2, 
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A possible mechanistic scheme for the formation of the B-ring fragmented products 27 
and 31 is outlined in Scheme 6. This mechanism is also consistent with the finding that 
27 was inert to reduction when treated with an excess amount of L-selectride under the 
reaction conditions indicated in Scheme 5 (b). Reaction of 21, via its tertiary nitrogen 
atom, with the dimethylchlorosulfonium species (Me2SCl+)21 would lead to the N-
sulfonium intermediate A which upon base assisted fragmentation could give rise to the 
iminum ion B (Scheme 6). DMSO assisted cyclization of B could lead to the bicyclic 
intermediate C which upon base promoted elimination-fragmentation would give the 
resonance stabilized cation intermediate D. Quenching of the reaction mixture with water 
could give rise to the aminal F which could give the lactam 27 upon chromatography on 
silica gel. Reduction of F with an excess amount of L-selectride could give alcohol 31 
(Scheme 6). 
The alcohol 28, however, clearly arises from reduction of the expected and desired C-7 
ketone 34, that could not be isolated in pure form, while alcohol 30 seems to have formed 
from reduction of ketone 35, the C-7a epimer of ketone 34 (Scheme 7 (a)). Such an 
epimerization process would seem likely as it would relieve unfavorable steric 
interactions between the substituents at C-1, C-2 and C-5 on the more crowded concave 
face of 34 (Scheme 7 (a)). In the C-7a epimeric ketone 35 these substituents are now on 
the less crowded convex face of the molecule. The isolation of ketone 29 in Scheme 5 (b), 
suggests that this compound was protected from reduction with L-selectride by formation 
of its corresponding enolate anion. A tentative mechanism to support such an enolate 
intermediate, which also accounts for the inversion of configuration at C-1, is shown in 
Scheme 7 (b). This mechanism involves formation of the enone G which upon 1,4-
17 
 
reduction by L-selectride, with addition of hydride at C-1 from the stereoelectronically 
favored pseudo-axial direction, would give an enolate anion which upon quenching with 
water and protonation at C-7a, from the stereoelectronically favored pseudo-axial 
direction, would give 29 (Scheme 7 (b)). 






















































































































The relatively more straight forward oxidation of alcohol 24 to its desired ketone 25 
(Scheme 4 (b)) is likely a consequence of the C-5 β-methyl substituent which would 















formation not favored 






Attempts to prepare the C-7 inverted alcohol 28 more efficiently by SN2 inversion 
reactions of the alcohol 21 were also unsuccessful (Scheme 9). The Mitsunobu reaction 
of 21 gave the p-nitrobenzoate 36 in very poor yield (8%) and with retention of 
configuration at C-7. The O-mesylate derivative 37 of 21 gave a more respectable yield 
of the benzoate 38, upon treatment with CsOBz22 however again with retention of 
configuration at C-7. The configuration of esters 36 and 38 were confirmed from there 
base hydrolysis back to the alcohol 21. While the Mitsunobu reaction of hindered 
alcohols can proceed with retention of configuration by direct O-acylation of the alcohol 
by [ArCO2PPh3]+,23 we suspect that the aziridinium ion intermediate H24 is formed in 
















Scheme 9. Attempts to invert the configuration at C-7 of alcohol 21.  
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A comparison of the 13C NMR chemical shifts (rounded up to the nearest whole integer) 
of synthetic compounds 2, 3, 5 and 6 (all with the same configurations at C-1 – C-3 and 
C-7a) and those of natural hyacinthacine B7 is shown in Figure 3. Compounds 2 and 5, 
with an α-methyl group at C-5, have nearly the same 13C NMR chemical shifts for C-3, 
C-5, C-8 and C-9. This is also true for compounds 3 and 6, having a β-methyl group at C-
5. However, these particular chemical shifts observed for compounds 3 and 6 are 
significantly downfield of those of their corresponding carbons seen in the 13C NMR 
spectra of compounds 2 and 5, except for the chemical shift of C-8 which is insensitive to 
the configuration at C-5. Interestingly, the 13C NMR chemical shifts for C-3, C-5, C-8 
and C-9 of hyacinthacine B4 4, the C-1 epimer of 5, and 5 are also nearly the same. 
21 
 
Compounds 2 and 3, with a β-hydroxy group at C-7, have nearly the same 13C NMR 
chemical shifts for C-1, C-7 and C-7a. This is also observed for compounds 5 and 6, 
having an α-hydroxy group at C-7. In compounds 2 and 3, C-7a resonates at δ 75-76, 
downfield of the signals for C-1 and C-7 (δ 71−74), while in the 13C NMR spectra of 
compounds 5 and 6, the reverse trend is observed (C-7a, δ 70-71 and C-1 and C-7 (δ 
75−76).  
In light of this analysis, an examination of the 13C NMR chemical shifts for C-3, C-5, C-8 
and C-9 of natural hyacinthacine B7 (Figure 2), would indicate the α-configuration of the 
C-5 methyl group rather than the assigned β-configuration. Further, if one assumes that 
the chemical shifts of C-1 (reported as δ 77.9) and C-2 (reported as δ 74.9) have been 
missassigned in natural hyacinthacine B7 [these chemical shifts are not consistent with 
those of the other hyacinthacine alkaloids (in compounds 2−6, the 13C NMR chemical 
shift of C-2 is always downfield of that of C-1, see SI)] then this compound should have 
the α-configuration at C-1 and not the initially assigned β-configuration. This analysis 
suggests that natural hyacinthacine B7 is actually hyacinthacine B5 5. Further, analysis of 
Table 1 indicates a close match between their 13C NMR chemical shifts. A comparison of 
the 1H NMR chemical shifts and coupling constants for these two alkaloids shows close 
agreement for the protons H-1, H-2, H-6β, H-7, H-8 and H-9 (Table 2) and a consistent 
difference of ca 0.2 ppm for the protons H-3, H-5, H-6α, H-7a and H-8'. Considering that 
the chemical shifts of these types of compounds are sensitive to pH and concentration 
effects4 these NMR data would seem to be a good match, and support our proposal that 
they are the same compound (hyacinthacine B5). Their specific rotations however, are of 
the same sign but differ significantly in magnitude (hyacinthacine B5: [α] D −25.4 (c 0.26, 
22 
 
H2O)3c; natural hyacinthacine B7: [α] D −4.4 (c 0.20, H2O)
3b). However, without having 
authentic samples of these two natural products in hand it is impossible to either verify or 

















































































Figure 2. 13C NMR chemical shifts (rounded to the nearest whole integer) of compounds 







Table 1. Comparison of literature 13C NMR chemical shifts (125 MHz, D2O) of 






hyacinthacine B5 3c 
δC (ppm) 
1 77.9 74.8 
2 74.9 76.9 
3 66.2 65.5 
5 57.7 58.5 
6 45.2 43.9 
7 76.5 75.0 
7a 69.9 70.1 
8 66.8 64.7 
9 18.4 17.9 
 
Table 2. Comparison of literature 1H NMR chemical shifts (500 MHz, D2O) of 
natural hyacinthacine B73d and natural hyacinthacine B53c 
 
proton 
natural hyacinthacine B73d  natural hyacinthacine B53c  
δH (ppm) Mult., J (Hz)  δH (ppm) Mult., J (Hz) 
1 4.35 t (4.4) 4.37 dd (4.4, 4.2) 
2 3.97 dd (7.6, 4.4) 4.08 dd (8.0, 4.2) 
3 3.29 ddd (7.6, 5.5, 3.5) 3.48 ddd (5.1, 4.6, 4.2) 
5 3.22 m 3.44 m  
6α 1.68 m 1.86 ddd (12.5, 10.0, 8.0) 
6β 2.16 m 2.22 ddd (12.5, 6.4, 6.0) 
7 4.50 m 4.55 ddd (8.0, 7.6, 6.4) 
7a 3.45 dd (7.6, 4.4) 3.66 dd (7.6, 4.4)  
8 3.57 dd (11.5, 3.5) 3.70 dd (12.0, 5.1) 
8′ 3.63 dd (11.5,5.5) 3.73 dd (12.0, 4.6) 






In conclusion, the total synthesis of hyacinthacines B3, B4, and B5, purported 
hyacinthacine B7, 7-epi- hyacinthacine B7, and 7a-epi- hyacinthacine B3, from a common 
anti-1,2-amino alcohol precursor (7), has been achieved. These syntheses have confirmed 
that the proposed structures and absolute configurations of hyacinthacines B3, B4, and B5 
are correct and disclosed that the proposed structure of natural hyacinthacine B7 was 
incorrect. Our synthetic and spectroscopic studies suggest that the natural hyacinthacines 
B5 and B7 are the same compound; however without access to authentic samples this 
cannot be unequivocally proven. 
EXPERIMENTAL SECTION 
General Methods. Flash column chromatography packed with Merck Kieselgel 60 
PF254 was used for purification. A single quadrupole mass spectrometer was used for 
obtaining the LRESIMS. Quadrupole time-of-flight mass spectrometers were used for 
acquiring HRESIMS and HRASAPMS. IR spectra were run on neat samples. 1H (500 or 
300 MHz) and 13C NMR (125 or 75 MHz) NMR spectra were recorded in 
deuterochloroform (CDCl3), deuterium oxide (D2O) or deuterated methanol-d4 (CD3OD) 
solution. All signals which were recorded in CDCl3 were relative to the tetramethylsilane 
(TMS) signal and the CDCl3 signal, referenced at 0.00 ppm (for 1H NMR) and 77.16 ppm, 
(for 13C NMR), respectively. All signals which were recorded in CD3OD were relative to 
the CD2HOD signal for 1H NMR and the CD3OD for 13C NMR, referenced at 3.31 ppm 
and 49.00 ppm, respectively. All signals which were recorded in D2O were relative to the 
D2O signal for 1H NMR, referenced at 4.49 ppm. For 13C NMR spectra in D2O the 
referencing of peaks is relative to internal MeOH (49.50 ppm). In some cases the 13C 
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NMR spectral data were referenced to sodium 3-(trimethylsilyl)propionate (TSP) at δ -
2.19 in D2O. In order to compare our 13C NMR data recorded in D2O (and referenced to 
internal MeOH) with those of the literature which were run in D2O and referenced to TSP 
at δ 0.00 we have added 2.19 ppm to our observed 13C NMR chemical shifts in the 13C 
NMR comparison tables (SI). NMR assignments were based upon gCOSY, APT, gHSQC, 
gHMBC and NOESY experiments. In some cases, 13C NMR signals that were absent in 
the standard 13C NMR spectrum were identified using gHSQC and gHMBC experiments. 
Petrol refers to the hydrocarbon fraction of bp. 40-60 °C. are named using systematic 
nomenclature. The NMR assignments made to pyrrolizidine compounds are based on the 
numbering system of the hyacinthacine alkaloids and not the systematic name. 
Synthesis of hyacinthacine B3 (2). 
(2R,4S)-4-(4-Methoxybenzyloxy)pentane-1,2-diol (13) A solution of 12 (2.58 g, 12.49 
mmol) in tert-butanol (20 mL) was slowly added dropwise into a solution of potassium 
ferric cyanide (12.34 g, 37.48 mmol), potassium carbonate (5.18 g, 37.48 mmol), 
methanesulfonamide (1.19 g, 12.49 mmol), potassium osmate dihydrate (55 mg, 0.150 
mmol) and (DHQD)2PYR (0.110 g, 0.125 mmol) in H2O (40 mL) which was cooled in an 
ice bath. The reaction mixture was stirred at 3 - 5 oC (in a cold room) for 2 d. The 
reaction was quenched with sodium sulfite (9.44 g, 74.94 mmol) and then allowed to 
warm to rt (21 oC), stirred for 30 min and then extracted with EtOAc (3 x 100 mL). The 
combined organic layers were dried (MgSO4) and concentrated in vacuo. Purification by 
flash column chromatography (increasing polarity from 0:100 to 4:96 of MeOH/CH2Cl2) 
gave the title compound as a colorless oil (2.736 g, 99 %, dr = 4:1). Rf  0.50 (10:90 
MeOH/CH2Cl2). [α] 25D - 46.5 (c 1.64, CHCl3). IR υmax (cm
-1): 3396, 2925, 1614, 1512, 
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1244, 1031, 818. δH (500 MHz, CDCl3): (major diastereomer) 7.25 (2H, d, J = 8.8 Hz), 
6.87 (2H, d, J = 8.8 Hz), 4.54 (1H, d, J = 11.2 Hz), 4.36 (1H, d, J = 11.2 Hz), 3.96 (1H, s 
(br), H2), 3.87 - 3.82 (1H, m, H4), 3.78 (3H, s), 3.56 (1H, dd, J = 10.8, 9.8 Hz, H1A), 
3.43 (1H, dd, J = 9.8, 7.3 Hz, H1B), 1.74 - 1.65 (1H, m, H3A), 1.55 (1H, ddd, J = 10.7, 7.8, 
2.9 Hz, H3B), 1.24 (3H, d, J = 6.3 Hz, H5). (minor diastereomer, in part) 4.59 (1H, d, J = 
11.2 Hz), 4.34 (1H, d, J = 11.2 Hz). δC (125 MHz, CDCl3): (major diastereomer) 159.3 
(ArC), 130.4 (ArC), 129.5 (2 x ArCH), 114.0 (2 x ArCH), 72.2 (C4), 70.3 (OCH2PMP), 
69.3 (C2), 66.9 (C1), 55.3 (OCH3), 39.3 (C3), 19.5 (C5). (minor diastereomer, in part) 
132.1 (ArC), 131.9 (ArC), 114.4 (ArCH), 71.9 (C4), 70.1 (OCH2PMP), 66.7 (C1), 33.9 
(C3), 19.7 (C5). ESIMS m/z 263 (100%) [M+Na]+. HRESIMS found 263.1258, calcd for 
C13H20O4Na, 263.1259 [M+Na]+. 
Oxidation of diol 13. A mixture of 13 (208 mg, 0.87 mmol), 2,2,6,6-tetramethyl-1-
piperidinyloxy free radical (TEMPO) (3 mg, 0.02 mmol), potassium bromide (113 mg, 
0.95 mmol), anhydrous CH2Cl2 (9.5 mL) and saturated aq NaHCO3 solution (3.8 mL) 
was cool to 0 oC. Commercial sodium hypochlorite solution (0.4 M, 3.0 mL, 1.21 mmol) 
was added slowly dropwise and stirred at 0 oC for 30 min. Saturated aq sodium 
thiosulfate solution (8.6 mL) was added at 0 oC. The reaction mixture was extracted with 
EtOAc (3 x 100 mL), dried (MgSO4), and concentrated in vacuo to give a white solid 
which was used in the subsequent Petasis reaction without further puricication. 
(3S,4R,6S,E)-3-((S)-1-(Benzyloxy)but-3-en-2-ylamino)-6-(4-methoxybenzyloxy)-4-
methoxy-1-phenylhept-1-en-4-ol (7). A solution of 10 (183 mg, 1.03 mmol) in anhydrous 
CH2Cl2 (0.5 mL) was added to a solution of the above crude oxidation product and (E)-2-
phenylvinylboronic acid (153 mg, 1.03 mmol) in 1,1,1,3,3,3-
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hexafluoroisopropanol/CH2Cl2 (1:9, 3.5 mL) under a nitrogen atmosphere. The reaction 
mixture was stirred at rt (32 oC) for 2 d, diluted with EtOAc (25 mL) and washed with 0.5 
M NaOH solution (3 x 25 mL). The organic layer was dried (MgSO4) and concentrated in 
vacuo to give a dark brown oil. Purification by flash column chromatography (0:100 to 
40:60 EtOAc/CH2Cl2 as eluent) gave the title compound (314 mg, 73 %, 2 steps) as a 
brown oil. Rf  0.45 (5:95 MeOH/CH2Cl2). [α] 25D  + 11.9 (c 0.56, CHCl3). IR υmax (cm
-1): 
3438, 3066, 3027, 2905, 2860, 1648, 1611, 1511, 1452, 1245, 1076, 1035, 975, 925, 818, 
746, 696. δH (500 MHz, CDCl3): 7.36 - 7.19 (12H, m), 6.8 (2H, d, J = 8.3, Hz), 6.43 (1H, 
d, J = 16.1 Hz, H1), 6.08 (1H, dd, J = 16.1, 8.3 Hz, H2), 5.63 - 5.56 (1H, m, H2′), 5.21 
(1H, d, J = 17.1 Hz, H3′trans), 5.17 (1H, d, J = 10.2 Hz, H3′cis), 4.51 (1H, d, , J = 11.2 
Hz), 4.49 (2H, s), 4.37 (1H, d, J = 11.2 Hz), 4.02 (1H, s (br), H4), 3.84 - 3.81 (1H, m, 
H6), 3.75 (3H, s), 3.49 - 3.42 (3H, m), 3.24 (1H, dd, J = 8.3, 3.4 Hz, H3), 1.58 (2H, dd, J 
= 6.4, 5.4 Hz, H5), 1.21 (3H, d, J = 6.4 Hz, H7). δC (125 MHz, CDCl3): 159.1 (ArC), 
138.2 (ArC), 138.0 (CH=), 136.9 (ArC), 132.8 (C1), 130.9 (ArC), 129.3 (2 x ArCH), 
128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.1 (C2), 127.7 (2 x ArCH), 127.5 (2 x ArCH), 
126.4 (2 x ArCH), 117.9 (=CH2), 113.8 (2 x ArCH), 73.4 (CH2), 73.0 (OCH2Ph), 72.2 
(C6), 70.4 (OCH2PMP), 70.4 (C4), 62.3 (C3), 58.0 (CH), 55.3 (OCH3), 40.2 (C5), 19.8 
(C7). ESIMS m/z 502 (100%) [M+H]+, HRESIMS found 502.2954, calc for C32H40NO4, 
502.2957 [M+H]+. 
(4S,5R)-3-((S)-1-(Benzyloxy)but-3-en-2-yl)-5-((S)-2-(4-methoxybenzyloxy)propyl)-4-
styryloxazolidin-2-one (15). Small scale reaction: Triphosgene (6 mg, 0.020 mmol) was 
slowly added to the solution of the 1,2-amino alcohol 7 (20 mg, 0.040 mmol) and 
triethylamine (11 µL, 0.080 mmol) in anhydrous CH2Cl2 (3 mL) at 0 oC under a nitrogen 
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atmosphere. After stirring for 15 min the reaction mixture was allowed to warm to rt, 
stirred for 18 h and then concentrated in vacuo to give a yellow solid. Purification by 
flash column chromatography (increasing polarity from 0:100 to 1:99 of MeOH/CH2Cl2 
as eluent) gave the title compound (17 mg, 81%) as a colorless oil. Larger scale reaction: 
Using triphosgene (0.186 g, 0.625 mmol), 7 (625 mg, 1.25 mmol) and triethylamine (697 
µL, 4.99 mmol) the title compound (0.435 g, 66%) was obtained as a colorless oil. Rf  
0.66 (2:98 MeOH/CH2Cl2). [α] 25D + 20.9 (c 0.05, CHCl3). IR υmax (cm
-1): 3028, 2966, 
2929, 2865, 1743, 1612, 1512, 1453, 1402, 1246, 1072, 1033, 977, 932, 820, 753, 695, 
608. δH (500 MHz, CDCl3): 7.33 - 7.23 (12H, m), 6.86 (2H, d, J = 8.3 Hz), 6.30 (1H, d, J 
= 15.9 Hz), 6.00 (1H, dd, J = 15.9, 9.8 Hz), 5.86 - 5.78 (1H, m), 5.25 (1H, d, J = 16.1 Hz), 
5.18 (1H, d, J = 10.2 Hz), 4.86 (1H, ddd, J = 10.3, 8.8, 1.5 Hz), 4.61 (1H, d, J = 11.7 Hz), 
4.52 (1H, d, J = 10.7 Hz), 4.47 (1H, d, J = 11.7 Hz), 4.37 - 4.40 (2H, m), 4.34 (1H, d, J = 
10.7 Hz), 3.89 (1H, dd, J = 10.0, 9.3 Hz), 3.83 - 3.81 (1H, m), 3.79 (3H, s), 3.61 (1H, dd, 
J = 10.0, 4.9 Hz), 1.70 (1H, td, J = 11.9, 2.0 Hz), 1.60 (1H, dd, J = 11.9, 11.2 Hz), 1.19 
(3H, d, J = 6.3 Hz). δC (75 MHz, CDCl3): 159.3 (ArC), 157.5 (CO), 138.0 (ArC), 135.8 
(ArC), 135.2 (=CHPh), 133.9 (CH=), 130.8 (ArC), 129.6 (2 x ArCH), 128.8 (ArCH), 
128.6 (2 x ArCH), 128.5 (ArCH), 128.1 (2 x ArCH), 128.0 (2 x ArCH), 126.8 (2 x 
ArCH), 125.1 (CH=), 118.6 (=CH2), 114.0 (2 x ArCH), 74.9 (C5), 73.2 (CH2), 71.5 (CH), 
71.1 (CH2), 69.1 (CH2), 61.4 (C4), 56.4 (CH), 55.4 (OCH3), 38.8 (CH2), 20.3 (Me). 
ESIMS m/z 550 (80%) [M+Na]+, 528 (18%) [M+H]+, HRESIMS found 528.2737, calcd 
for C33H38NO5, 528.2750 [M+H]+.   
(1R,5S,7aS)-5-(Benzyloxymethyl)-1-((S)-2-(4-methoxybenzyloxy)propyl)-1,7a-
dihydropyrrolo[1,2-c]oxazol-3(5H)-one (16). A solution of the oxazolidinone 15 (239 mg, 
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0.45 mmol) and Grubbs’ II ruthenium catalyst (19 mg, 0.02 mmol) in anhydrous CH2Cl2 
(8 mL) under a nitrogen atmosphere was heated at reflux for 18 h. The reaction mixture 
was cooled to rt and was then concentrated in vacuo to give a black semi-solid. 
Purification by flash column chromatography with increasing polarity from 0:100 to 
30:70 of EtOAc/petrol as eluent gave the title compound (172 mg, 90%) as a yellow oil. 
Rf 0.24 (30:70 EtOAc/petrol). [α] 25D
 - 22.5 (c 0.12, CHCl3). IR υmax (cm-1): 2967, 2864, 
1745, 1610, 1513, 1454, 1375, 1246, 1213, 1072, 820, 746, 697, 608. δH (500 MHz, 
CDCl3): 7.34 - 7.23 (7H, m), 6.86 (2H, d, J = 8.3 Hz), 5.99 (1H, d, J = 5.9 Hz), 5.89 (1H, 
d, J = 5.9 Hz), 4.98 (1H, td, J = 9.3, 3.4 Hz), 4.80 - 4.76 (2H, m), 4.55 (1H, d, J = 11.2 
Hz), 4.54 (2H, s),  4.33 (1H, d, J = 11.2 Hz), 3.79 - 3.75 (1H, m), 3.78 (3H, s), 3.52 (2H, 
d, J = 4.5 Hz), 1.72 (1H, ddd, J = 12.4, 10.7, 3.4 Hz), 1.62 (1H, ddd, J = 10.7, 9.3, 2.9 
Hz), 1.21 (3H, d, J = 5.8 Hz). δC (125 MHz, CDCl3): 162.4 (C3), 159.3 (ArC), 138.0 
(ArC), 132.9 (C7), 130.6 (ArC), 129.5 (2 x ArCH), 128.5 (C6), 128.4 (2 x ArCH), 127.7 
(ArCH), 127.6 (2 x ArCH), 113.9 (2 x ArCH), 76.4 (C1), 73.3 (OCH2Ph), 71.4 (CH2), 
71.2 (CH), 70.9 (CH2), 68.2 (C5), 67.0 (C7a), 55.3 (OCH3), 40.1 (CH2), 20.0 (Me). 




methylmorpholine-N-oxide (335 mg, 2.86 mmol) and potassium osmate dihydrate (26 mg, 
0.07 mmol) were added to a solution of 16 (605 mg, 1.43 mmol) in 3:1 acetone/water (18 
mL). The reaction mixture was stirred at 35 oC for 18 h, concentrated in vacuo, diluted 
with H2O and extracted with EtOAc (3 x 30 mL). The combined organic layers were 
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dried (MgSO4) and concentrated in vacuo to afford a black oil. Purification by flash 
column chromatography (0:100 to 3:97 MeOH/CH2Cl2 as eluent) gave the title compound 
(629 mg, 96%) as a yellow oil. Rf  0.18 (60:40 EtOAc/petrol). [α] 25D
 + 6.2 (c 0.14, CHCl3). 
IR υmax (cm-1): 3402, 2931, 2863, 1723, 1612, 1513, 1455, 1370, 1303, 1245, 1176, 1121, 
1061, 1031, 950, 821, 741, 698. δH (500 MHz, CDCl3): 7.31 - 7.20 (5H, m), 6.85 - 6.84 
(2H, m), 4.86 - 4.83 (1H, m), 4.60 - 4.51 (3H, m), 4.30 (1H, d, J = 10.7 Hz) 4.24 (1H, s 
(br)), 3.91 (1H, s (br)), 3.78 (3H, s), 3.76 - 3.74 (1H, m), 3.69 - 3.67 (1H, m), 3.65 - 3.63 
(3H, m), 2.35 (1H, ddd, J = 10.5, 8.8, 3.4 Hz), 1.92 (1H, td, J = 10.5, 4.4 Hz), 1.22 (3H, d, 
J = 4.9 Hz). δC (125 MHz, CDCl3): 163.0 (C3), 159.3 (ArC), 138.0 (ArC), 130.6 (ArC), 
129.6 (2 x ArCH), 128.5 (2 x ArCH), 127.8 (ArCH), 127.7 (2 x ArCH), 113.9 (2 x 
ArCH), 76.0 (C7), 74.0 (C1), 73.5 (CH2), 72.3 (C6), 72.2 (CH), 70.7 (CH2), 70.3 (CH2), 
65.2 (C7a), 62.5 (C5), 55.4 (OCH3), 37.5 (CH2), 20.0 (Me). ESIMS m/z 480 (100%) 
[M+Na]+, 458 (10%) [M+H]+, HRESIMS found 458.2187, calcd for C25H32NO7, 
458.2179 [M+H]+. 
(1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-1-((S)-2-(4-
methoxybenzyloxy)propyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one (18): A solution of 
the diol 17 (18 mg, 0.039 mmol) and tetrabutylammonium iodide (TBAI) (1 mg, 0.004 
mmol) in anhydrous THF (5 mL) was stirred at rt (18 oC) for 15 min under a nitrogen 
atmosphere. Benzyl bromide (20 µL, 0.157 mmol) was added and then the solution was 
cooled to 0 oC. Sodium hydride (50% dispersion in mineral oil, 6 mg, 0.117 mmol) was 
slowly added and the reaction mixture was allowed to warm to rt and was stirred for 18 h. 
Quenching with H2O (50 mL) gave a cloudy mixture, which was extracted with CH2Cl2 
(3 x 100 mL). The combined organic layers were dried (MgSO4) and concentrated in 
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vacuo to give a light yellow solid. Purification by flash column chromatography (0:100 to 
30:70 EtOAc/petrol as eluent) gave the title compound (25 mg, 100%) as a colorless oil. 
Rf  0.70 (60:40 EtOAc/petrol). [α] 25D
 + 29.1 (c 0.14, CHCl3). IR υmax (cm-1): 3031, 2929, 
2862, 1750, 1611, 1513, 1455, 1390, 1359, 1303, 1246, 1228, 1065, 1031, 821, 736, 698. 
δH  (500 MHz, CDCl3): 7.32 - 7.18 (17H, m), 6.84 (2H, d, J = 7.3 Hz), 4.99 (1H, d, J = 
11.2 Hz), 4.77 (1H, dt, J = 7.8, 6.6 Hz), 4.58 - 4.48 (4H, m), 4.40 (1H, d, J = 12.2 Hz), 
4.37 (1H, d, J = 12.2 Hz), 4.22 (1H, d, J = 10.7 Hz), 4.15 (1H, dd, J = 7.8, 1.5 Hz), 3.97 
(1H, dd, J = 7.8, 2.4 Hz), 3.93 (1H, s (br)), 3.77 - 3.75 (1H, m), 3.73 (3H, s), 3.66 - 3.61 
(2H, m), 3.56 (1H, dd, J = 10.2, 2.0 Hz), 2.09 (1H, dd, J = 14.2, 7.1 Hz), 1.79 - 1.75 (1H, 
m), 1.07 (3H, d, J = 5.9 Hz). δC (125 MHz, CDCl3): 162.1 (C3), 159.4 (ArC), 138.3 
(ArC), 138.1 (ArC), 137.7 (ArC), 130.7 (ArC), 129.6 (2 x ArCH), 128.6 (2 x ArCH), 
128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.1 (ArCH), 127.8 (5 x ArCH), 127.5 (ArCH), 
127.3 (2 x ArCH), 114.0 (2 x ArCH), 83.3 (C6), 77.2 (C7), 73.9 (C1), 73.4 (CH2), 73.3 
(CH2), 73.0 (CH2), 72.3 (CH), 70.8 (CH2), 69.3 (CH2), 64.4 (C7a), 61.1 (C5), 55.4 
(OCH3), 37.4 (CH2), 19.9 (Me). ESIMS m/z 660 (70%) [M+Na]+, 638 (3%) [M+H]+, 
HRESIMS found 638.3093, calcd for C39H44NO7, 638.3118 [M+H]+. 
(1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-1-((S)-2-
hydroxypropyl)tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one (19). Dichloro-5,6-
dicyanobenzoquinone (103 g, 0.45 mmol) was added to a solution of 18 (131 mg, 0.21 
mmol) in CH2Cl2/H2O (8:1, 9 mL). The reaction mixture was stirred at rt (26 oC) until 
TLC analysis (50:50 EtOAc/petrol) showed complete consumption of 18 (4 h). 
Purification by flash column chromatography (increasing polarity from 50:50 to 80:20 of 
EtOAc/petrol as eluent) gave the title compound (94 mg, 89%) as a yellow oil. Rf  0.23 
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(50:50 EtOAc/petrol). [α] 25D
 + 19.7 (c 0.08, CHCl3). IR υmax (cm-1): 3452, 2972, 2864, 
1742, 1511, 1397, 1361, 1231, 1206, 1127, 1071, 739, 699. δH (500 MHz, CDCl3): 7.33 - 
7.23 (15H, m), 5.04 (1H, d, J = 11.7 Hz), 4.79 (1H, ddd, J = 12.7, 8.3, 2.9 Hz), 4.65 (1H, 
d, J = 11.7 Hz), 4.57 - 4.50 (3H, m), 4.40 (1H, d, J = 12.2 Hz), 4.28 (1H, d, J = 7.8 Hz), 
4.03 (1H, s), 3.99 - 3.98 (1H, m), 3.92 - 3.88 (1H, m), 3.76 (1H, dd, J = 10.2, 2.4 Hz), 
3.73 (1H, d, J = 7.8 Hz), 3.60 (1H, dd, J = 10.2, 2.4 Hz), 2.09 (1H, ddd, J = 14.4, 8.3, 2.4 
Hz), 1.64 (1H, ddd, J = 14.4, 9.8, 4.4 Hz), 1.07 (3H, d, J = 6.4 Hz). δC (125 MHz, CDCl3): 
162.2 (C3), 138.2 (ArC), 138.1 (ArC), 137.7 (ArC), 128.6 (2 x ArCH), 128.5 (2 x ArCH), 
128.4 (2 x ArCH), 128.1 (ArCH), 127.8 (5 x ArCH), 127.6 (ArCH), 127.4 (2 x ArCH), 
83.4 (C6), 76.9 (C7), 74.0 (C1), 73.4 (2 x CH2), 73.0 (CH2), 69.4 (CH2), 65.2 (CH), 64.4 
(C7a), 61.1 (C5), 38.3 (CH2), 24.5 (Me). ESIMS m/z 540 (100%) [M+Na]+, 518 (48%) 
[M+H]+, HRESIMS found 518.2523, calcd for C31H36NO6, 518.2543 [M+H]+. 
General method for hydrolysis of oxazolidinones  
(1R,3S)-1-((2R,3S,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)pyrrolidin-2-yl)butane-
1,3-diol (20): Sodium hydroxide (38 mg, 1.66 mmol) and 3 drops of H2O were added to a 
solution of 19 (171 mg, 0.33 mmol) in ethanol (3 mL). The reaction mixture was stirred 
and irradiated in a CEM microwave reactor (the temperature control was set at 110 oC 
and the maximum applied power at 200 W) for 1 h. After the reaction mixture had cooled 
to rt it was concentrated in vacuo to give a yellow semi-solid. Purification by flash 
column chromatography (increasing polarity from 0:100 to 8:92 of MeOH/CH2Cl2 as 
eluent) gave the title compound (156 mg, 96%) as a colorless oil. Rf  0.32 (7.5:92.5 
MeOH/CH2Cl2). [α] 25D
 + 31.3 (c 0.06, CHCl3). IR υmax (cm-1): 3355, 3029, 2894, 2858, 
1494, 1451, 1405, 1344, 1208, 1145, 1084, 1051, 731, 694, 656. δH (500 MHz, CDCl3): 
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7.35 - 7.24 (15H), 4.85 (1H, d, J = 11.2 Hz), 4.60 (1H, d, J = 12.2 Hz), 4.55 (1H, d, J = 
12.2 Hz), 4.53 (1H, d, J = 11.2 Hz), 4.49 (1H, d, J = 11.7 Hz), 4.43 (1H, d, J = 11.7 Hz), 
4.15 - 4.12 (2H, m, J = 5.0 Hz), 3.99 - 3.96 (1H, m), 3.90 (1H, dd, J = 5.4, 5.0 Hz), 3.53 - 
3.47 (2H, m), 3.46 - 3.44 (1H, m), 3.10 (1H, dd, J = 8.3, 5.4 Hz), 1.71 (1H, ddd, J = 14.4, 
5.4, 2.4 Hz), 1.65 (1H, ddd, J = 14.4, 8.8, 5.8 Hz), 1.18 (3H, d, J = 6.4 Hz). δC (75 MHz, 
CDCl3): 138.0 (ArC), 137.9 (ArC), 137.8 (ArC), 128.6 (2 x ArCH), 128.5 (4 x ArCH), 
128.2 (3 x ArCH), 128.1 (3 x ArCH), 128.0 (ArCH), 127.9 (2 x ArCH), 80.6 (C4), 79.8 
(C3), 73.4 (CH2), 73.3 (CH2), 72.6 (CH2), 70.4 (CH), 69.8 (CH2), 65.3 (CH), 63.1 (C2), 
60.7 (C5), 44.6 (CH2), 23.9 (Me). ESIMS m/z 492 (100%) [M+H]+, HRESIMS found 
492.2758, calcd for C30H38NO5, 492.2750 [M+H]+. 
General method for mesylation-cyclization 
(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-ol (21). Triethylamine (40 µL, 0.25 mmol) was slowly added to a solution of 
20 (140 mg, 0.25 mmol) in CH2Cl2 (12.8 mL) at 0 oC under a nitrogen atmosphere 
followed by a 0.13 M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.2 mL, 
0.28 mmol MeSO2Cl). The reaction mixture was stirred at 0 oC for 1.5 h and quenched 
with sat. aqueous NaHCO3 solution (3.5 mL) and extracted with CH2Cl2 (3 x 15 mL). 
The combined organic extracts were dried (MgSO4) and concentrated in vacuo to give a 
yellow oil. Purification by flash column chromatography (increasing polarity from 2:98 
to 10:90 of MeOH/CH2Cl2 as eluent) gave compound 21 (134 mg, 100%) as a colorless 
oil. Rf  0.22 (5:95 MeOH/CH2Cl2). [α] 25D
 + 16.5 (c 0.26, CHCl3). IR υmax (cm-1): 3354, 
2913, 2865, 1453, 1360, 1207, 1139, 1090, 1026, 732, 696. δH (500 MHz, CDCl3): 7.33 - 
7.27 (15H, m), 4.71 (1H, d, J = 12.2 Hz), 4.66 (1H, dd, J = 8.8, 4.4 Hz), 4.58 - 4.50 (5H, 
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m), 4.14 (1H, dd, J = 5.4, 4.9 Hz), 3.90 (1H, dd, J = 5.0, 4.4 Hz), 3.70 - 3.67 (1H, m), 
3.58 (1H, dd, J = 4.9, 4.4 Hz), 3.45 - 3.43 (1H, m), 3.39 - 3.36 (2H, m), 1.85 (2H, dd, J = 
7.3, 5.4 Hz), 1.17 (3H, d, J = 6.8 Hz). δC (125 MHz, CDCl3): 138.4 (ArC), 138.3 (ArC) 
138.2 (ArC), 128.5 (2 x ArCH), 128.4 (4 x ArCH), 127.9 (5 x ArCH), 127.8 (3 x ArCH), 
127.7 (ArCH), 81.2 (C2), 76.6 (C1), 75.8 (C7a), 73.5 (CH2), 73.1 (CH2), 72.2 (CH2), 71.8 
(C8), 71.3 (C7),  60.2 (C3), 56.9 (C5), 42.4 (C6), 16.2 (C9). ESIMS m/z 474 (100%) 
[M+H]+, HRESIMS found 474.2624, calcd for C30H36NO4, 474.2644 [M+H]+. 
General method for hydrogenolysis of benzyl ethers  
(1S,2R,3R,5R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-1,2,7-triol 
(hyacinthacine B3) (2). PdCl2 (7 mg, 0.04 mmol) was added to a N2 flushed solution of 21 
(17 mg, 0.036 mmol) in MeOH (4 mL). The reaction mixture was then stirred at rt under 
a H2 atmosphere (balloon) for 8 h and then filtered through a pad of celite and washed 
with MeOH (10 mL). The combined filtrates were concentrated in vacuo to give a 
colorless film which was dissolved in water (2 mL) and held for 15 min in a column 
containing Amberlyst A-26 (OH-) ion-exchange resin (1 g). Elution with water (3 x 5 mL) 
followed by evaporation in vacuo gave the title compound (5 mg, 68%) as a colorless 
film. [α] 23D
 + 10.8 (c 0.33, H2O). [Lit.3b [α] D  + 3.1 (c 0.33, H2O), temperature not reported]. 
IR υmax (cm-1): 3317, 2960, 2929, 2878, 1652, 1338, 1133. δH (500 MHz, CD3OD): 4.52 
(1H, m, H7), 4.04 (1H, t, J = 4.4 Hz, H1), 3.91 (1H, dd, J = 4.2, 7.3 Hz, H2), 3.57 (1H, 
dd, J = 4.9, 11.0 Hz, H8Α), 3.53 (1H, dd, J = 4.5, 11.1 Hz, H8Β), 3.50 (1H, m, H5), 3.30 
(1H, t, J = 4.6 Hz, H7a), 3.10 (1H, ddd, J = 4.7, 4.9 7.3 Hz, H3), 1.86-1.82 (2H, m, H6α 
and H6β), 1.19 (3H, d, J = 6.9 Hz, H9). δH (75 MHz, CD3OD): 76.5 (C2), 76.2 (C7a), 
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71.4 (C1), 70.6 (C7), 64.2 (C8), 63.0 (C3), 56.4 (C5), 43.5 (C6), 16.7 (C9). ESIMS m/z 
204 (100%) [M+H]+. HRMS found 204.1232, calcd for C9H18NO4, 204.1236 [M+H]+. 
Synthesis of hyacinthacine B7 (3) and 7-epi-hyacinthacine B7 (6) 
General method for the Mitsunobu reaction 
(R)-1-((1R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-
oxohexahydropyrrolo[1,2-c]oxazol-1-yl)propan-2-yl 4-nitrobenzoate (22). A solution of 
19 (455 mg, 0.88 mmol), triphenylphosphine (1038 mg, 3.96 mmol) and p-nitrobenzoic 
acid (662 mg, 3.959 mmol) in toluene (9 mL) was cool to 0 oC and diisopropyl 
azodicarboxylate (0.78 mL, 3.96 mmol) was added. The reaction mixture was allowed to 
warm to rt (27 oC) and stirred for 24 h. The volatiles were removed in vacuo, extracted 
with CH2Cl2 (3 x 30 mL), dried (MgSO4) and concentrated in vacuo to give a dark brown 
oil. Purification by flash column chromatography (increasing polarity from 0:100 to 
10:90 of MeOH/CH2Cl2 as eluent) gave the title compound (498 mg, 85%) as a yellow oil. 
Rf 0.30 (30:70 EtOAc/petrol). [α] 25D
 - 26.6 (c 0.64, CHCl3). IR υmax (cm-1): 2934, 2864, 
1752, 1719, 1525, 1346, 1274, 1100, 737. δH (500 MHz, CDCl3): 8.24 (2H, d, J = 8.8 Hz), 
8.13 (2H, d, J = 8.8 Hz), 7.35 - 7.20 (15H, m), 5.27 - 5.21 (1H, m), 5.10 (1H, d, J = 11.7 
Hz), 4.72 (1H, dt, J = 7.3, 6.6 Hz), 4.66 (1H, d, J = 11.7 Hz), 4.57 (1H, d, J = 11.7 Hz), 
4.52 (1H, d, J = 11.7 Hz), 4.51 (1H, d, J = 11.7 Hz), 4.38 (1H, d, J = 11.7 Hz), 4.32 (1H, 
dd, J = 7.8, 2.0 Hz), 4.07 (1H, s, H7), 4.00 (1H, dt, J = 7.8, 2.9 Hz), 3.76 (2H, d, J = 8.3 
Hz), 3.59 (1H, J = 10.3, 2.4 Hz), 2.42 (1H, dt, J = 14.6, 7.8 Hz), 2.07 (1H, dt, J = 14.6, 
4.4 Hz), 1.31 (3H, d, J = 6.4 Hz). δC (125 MHz, CDCl3): 164.2 (CO), 161.8 (C3), 150.6 
(ArC), 138.1 (ArC), 137.8 (ArC), 137.4 (ArC), 135.7 (ArC), 130.8 (2 x ArCH), 128.6 (2 
x ArCH), 128.5 (2 x ArCH), 128.4 (2 x ArCH), 128.2 (ArCH), 127.8 (6 x ArCH), 127.7 
36 
 
(2 x ArCH), 127.4 (2 x ArCH), 123.6 (2 x ArCH), 83.3 (C6), 76.7 (C7), 73.4 (2 x CH2), 
73.0 (CH2), 72.8 (C1), 70.3 (CH), 69.2 (CH2), 63.9 (C7a), 61.1 (C5), 35.5 (CH2), 22.1 
(Me). ESIMS m/z 667 (100%) [M+H]+. HRASAPMS found 667.2671, calcd for 
C38H39N2O9, 667.2656 [M+H]+ 
(1R,3R)-1-((2R,3S,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)pyrrolidin-2-yl)butane-
1,3-diol (23). Following the general method for hydrolysis of an oxazolidinone, 
compound 22 (167 mg, 0.25 mmol) was treated with sodium hydroxide (58 mg, 2.51 
mmol) in ethanol (3 mL) and 3 drops of H2O at 110 oC in a CEM microwave reactor. 
Purification by flash column chromatography (0:100 to 5:95 MeOH/CH2Cl2 as eluent) 
gave the title compound (120 mg, 97%) as a colorless oil. Rf  0.30 (5:95 MeOH/CH2Cl2). 
[α] 25D
 + 18.7 (c 0.83, CHCl3). IR υmax (cm-1): 3323, 3030, 2864, 1496, 1453, 1360, 1208, 
1075, 915, 835, 736, 640. δH (500 MHz, CDCl3): 7.33 - 7.27 (15H), 4.88 (1H, d, J = 11.7 
Hz), 4.61 (1H, d, J = 11.7 Hz), 4.56 (1H, d, J = 11.7 Hz), 4.53 (1H, d, J = 11.7 Hz), 4.50 
(1H, d, J = 12.2 Hz), 4.44 (1H, d, J = 12.2 Hz,), 4.17 (1H, t, J = 4.4 Hz), 4.08-4.05 (1H, 
m), 4.03 - 4.01 (1H, m), 3.89 (1H, dd, J = 5.8, 4.4 Hz), 3.54 (1H, dd, J = 11.2, 5.4 Hz), 
3.48 - 3.46 (2H, m), 3.02 (1H, dd, J = 7.3, 4.4 Hz), 1.72 (1H, d,  J = 14.2 Hz), 1.44 (1H, 
dt, J = 14.2, 9.8 Hz), 1.16 (3H, d, J = 5.8 Hz). δC (125 MHz, CDCl3): 138.1 (ArC), 138.0 
(ArC), 137.9 (ArC), 128.7 (2 x ArCH), 128.5 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (3 x 
ArCH), 128.0 (3 x ArCH), 127.8 (3 x ArCH), 81.3 (C4), 79.2 (CH), 73.5 (CH2), 73.3 
(CH2), 72.9 (C3), 72.8 (CH2), 70.2 (CH2), 68.3 (CH), 63.1 (C2), 60.4 (C5), 42.6 (CH2), 
23.8 (Me). ESIMS m/z 492 (100%) [M+H]+, HRESIMS found 492.2765, calcd for 




pyrrolizin-1-ol (24). Following the general method for mesylation-cyclization, compound 
23 (259 mg, 0.53 mmol) was treated with triethylamine (73 µL, 0.53 mmol), 0.13 M 
solution of methanesulfonyl chloride in anhydrous CH2Cl2 (4.04 mL, 0.53 mmol 
MeSO2Cl) in CH2Cl2 (28 mL) at 0 oC for 1.5 h. Purification by flash column 
chromatography (0:100 to 10:90 MeOH/CH2Cl2 as eluent) gave the title compound (198 
mg, 77%) as a colorless oil. Rf  0.30 (5:95 MeOH/CH2Cl2). [α] 25D  + 21.7 (c 1.03, CHCl3). 
IR υmax (cm-1): 3360, 3030, 2922, 2862, 1469, 1452, 1359, 1310, 1208, 1094, 1048, 1027, 
914, 735, 696. δH (500 MHz, CDCl3): 7.32 - 7.27 (15H, m), 4.74 (1H, J = 11.7 Hz), 4.67 
(1H, td, 7.8, 6.6), 4.55 - 4.48 (5H, m), 4.06 (1H, t, J = 4.6 Hz), 3.92 (1H, dd, J = 5.6, 4.4 
Hz), 3.45 - 3.41 (3H, m), 3.09 (1H, dd, J = 10.1, 5.6 Hz), 3.06 - 3.02 (1H, m), 2.27 (1H, 
dt, J = 11.9, 6.1 Hz), 1.59 (1H, td, J = 11.9, 9.8 Hz), 1.14 (3H, d, J = 6.1 Hz). δC (75 MHz, 
CDCl3): 138.7 (ArC), 138.5 (ArC) 138.2 (ArC), 128.5 (4 x ArCH), 128.4 (2 x ArCH), 
127.9 (4 x ArCH), 127.8 (2 x ArCH), 127.7 (3 x ArCH), 82.0 (C2), 77.6 (C1), 73.4 (CH2), 
73.3 (C7a), 73.2 (CH2), 72.4 (CH2), 71.7 (C8), 71.0 (C7), 68.2 (C3), 62.4 (C5), 44.0 (C6), 
22.0 (C9). ESIMS m/z 474 (100%) [M+H]+, HRESIMS found 474.2665, calcd for 
C30H36NO4, 474.2644 [M+H]+. 
(1S,2R,3S,5R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-1,2,7-triol 
(putative hyacinthacine B7) (3). Following the general method for hydrogenolysis of 
benzyl ethers, the alcohol 24 (27 mg, 0.059 mmol) was treated with PdCl2 (16 mg, 0.09 
mmol) and MeOH (2 mL) at rt for 3 h. The title compound (10 mg, 84 %) was obtained 
as a colorless film. [α] 24D
 + 31.2 (c 0.20, CHCl3). δH (500 MHz, D2O): 4.60 (1H, ddd, J = 
5.8, 7.0, 9.2 Hz), 4.13 (1H, app. t, J = 4.0 Hz), 4.03 (1H, dd, J = 4.0, 9.1 Hz), 3.74 (1H, 
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dd, J = 4.9, 11.7 Hz), 3.70 (1H, dd, J = 4.9, 11.7 Hz), 3.32 (1H, dd, J = 4.0, 5.8 Hz), 3.06 
- 2.97 (1H, m), 2.81 (1H, app. dd, J = 4.9, 9.1 Hz), 2.38 (1H, ddd, J = 5.0, 7.0, 12.2 Hz), 
1.60 (1H, ddd, J = 9.3, 11.0, 12.2 Hz), 1.17 (1H, d, J = 6.3 Hz). δC (125 MHz, D2O): 80.3 
(C2), 75.8 (C1), 74.0 (C3), 73.5 (C7), 77.6 (C7a), 67.8 (C8), 67.4 (C5), 48.4 (C6), 24.7 
(C9). ESIMS m/z 204 (100%) [M+H]+. 
General method for Swern oxidation 
(3S,5R,6R,7S,7aS)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-one (25). Oxalyl chloride (79 µL, 0.92 mmol) was dropwise via syringe in to 
a stirred solution of DMSO (130 µL, 1.84 mmol) in CH2Cl2 (5 mL) at -78 oC. The 
solution was stirred at -78 oC for 5 min and then a solution of 24 (43 mg, 0.09 mmol) in 
CH2Cl2 (2 mL) cooled to -78 oC was added dropwise via syringe, followed by Et3N (513 
µL, 3.68 mmol). The reaction mixture was stirred at -78 oC for 1 h and then poured into 
H2O (40 mL) and extracted with Et2O (3 x 30 mL). The combined organic extracts were 
washed with brine, dried (MgSO4), and concentrated in vacuo to give a yellow oil. 
Purification by flash column chromatography (increasing polarity from 0:100 to 10:90 of 
MeOH/CH2Cl2 as eluent) gave the title compound 25 (27 mg, 63%) as a colorless oil, and 
recovered 24 (13.2 mg, 30%). Rf  0.61 (5:95 MeOH/CH2Cl2). [α] 25D + 28.2 (c 0.32, 
CHCl3). IR υmax (cm-1): 3030, 2864, 1750, 1698, 1452, 1361, 1270, 1207, 1098, 736, 661. 
δH (500 MHz, CDCl3): 7.32 - 7.23 (15H, m), 4.65 (1H, d, J = 11.7 Hz), 4.60 (1H, d, J = 
12.2 Hz), 4.59 (1H, d, J = 11.7 Hz), 4.51 (1H, d, J = 12.2 Hz), 4.50 (1H, d, J = 11.7 Hz), 
4.36 (1H, d, J = 11.7 Hz), 4.18 (1H, t, J = 3.4 Hz), 3.91 (1H, dd, J = 8.8, 3.4 Hz), 3.69 
(1H, d, J = 3.4 Hz), 3.63 (1H, dd, J = 9.8, 3.4 Hz), 3.56 (1H, dd, J = 9.8, 4.9 Hz), 3.50 - 
3.46 (1H, m), 3.35 (1H, dt, J = 8.8, 4.4 Hz), 2.61 (1H, dd, J = 17.6, 6.8 Hz), 2.10 (1H, dd, 
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J  = 17.6, 8.3 Hz), 1.21 (3H, d, J = 5.9 Hz). δC (125 MHz, CDCl3): 214.7 (C7), 138.5 
(ArC), 138.4 (ArC), 137.9 (ArC), 128.5 (2 x ArCH), 128.4 (4 x ArCH), 128.0 (3 x ArCH), 
127.9 (4 x ArCH), 127.8 (2 x ArCH), 83.4 (C2), 78.8 (C1), 73.8 (CH2), 73.5 (CH2), 73.1 
(CH2), 72.0 (C8), 71.8 (C7a), 69.1 (C3), 60.7 (C5), 46.6 (C6), 22.5 (C9). ESIMS m/z 472 
(100%) [M+H]+. HRASAPMS found 472.2494, calcd for C30H34NO4, 472.2488 [M+H]+.   
General method for the reduction of a ketone to a secondary alcohol with L-
selectride® 
(1S,3S,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-ol (26). A solution of the cyclic ketone 25 (63 mg, 0.13 mmol) in THF (5 mL) 
was cooled to -78 oC and then L-selectride® (1.0 M solution in THF, 536 µL, 0.54 mmol) 
was slowly added dropwise. The reaction mixture was stirred at -78 oC for 1 h, warm to rt 
(22 oC) and stirred for 2 h. Ammonia solution (1.0 M, 24 mL) was added and the 
resulting mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts 
was washed with brine, dried (K2CO3) and concentrated in vacuo to give a light brown 
film. Purification by flash column chromatography (increasing polarity from 0:100 to 
10:90 of MeOH/CH2Cl2 as eluent) gave the title compound (44 mg, 70%) as a colorless 
oil. Rf  0.34 (5:95 MeOH/CH2Cl2). [α] 25D + 36.2 (c 1.26, CHCl3). IR υmax (cm
-1): 3415, 
3030, 2864, 1696, 1452, 1363, 1204, 1098, 1024, 736, 697. δH (500 MHz, CDCl3): 7.33 - 
7.28 (15H, m), 4.74 (1H, d, J = 11.6 Hz), 4.59 (2H, s), 4.53 (2H, s), 4.48 (1H, d, J = 11.6 
Hz), 4.37 - 4.33 (2H, m), 4.02 (1H, dd, J = 5.4, 4.9 Hz), 3.80 (1H, s (br)), 3.53 (1H, s 
(br)), 3.47 - 3.41 (2H, m), 3.33 (1H, s (br)), 2.08 (1H, dd, J = 12.7, 5.4 Hz), 1.60-1.56 
(1H, m), 1.20 (3H, d, J = 4.4 Hz). δC (125 MHz, CDCl3): 138.2 (ArC), 137.6 (ArC), 
137.5 (ArC), 128.8 (2 x ArCH), 128.7 (2 x ArCH), 128.6 (2 x ArCH), 128.3 (2 x ArCH),  
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128.1 (4 x ArCH), 128.0 (ArCH), 127.8 (2 x ArCH), 80.6 (C2), 78.6 (C1, br), 73.6 (CH2), 
73.5 (CH2), 73.2 (C7), 72.9 (CH2), 71.2 (C8, br), 70.1 (C7a), 69.3 (C3), 62.3 (C5, br), 
45.0 (C6), 21.4 (C9, br). ESIMS m/z 474 [M+H]+. HRASAPMS found 474.2642, calcd 
for C30H36NO4, 474.2644 [M+H]+. 
(1S,2R,3R,5S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-1,2,7-triol 
(7-epi-hyacinthacine B7) (6). Following the general method for hydrogenolysis of benzyl 
ethers, the alcohol 26 (38 mg, 0.08 mmol) was treated with PdCl2 (22 mg, 0.12 mmol) 
and MeOH (6 mL) at rt for 3 h. The title compound (14 mg, 84%) was obtained as a 
colorless film. [α] 25D
 + 18.5 (c 0.14, H2O). IR υmax (cm-1): 3287, 2929, 1589, 1381, 1344, 
1199, 1127, 1081. δH (500 MHz, D2O): 4.59 (1H, t, J = 4.9 Hz, H7), 4.41 (1H, dd, J = 5.4, 
4.9 Hz, H1), 3.99 (1H, dd, J = 7.3, 4.9 Hz, H2), 3.71 (1H, dd, J = 11.7, 5.4 Hz, H8A), 3.67 
(1H, dd, J = 11.7, 5.8 Hz, H8B), 3.58 (1H, t, J = 5.4 Hz, H7a), 3.40 - 3.32 (1H, m, H5), 
3.04 (1H, app. dt, J = 6.3, 5.4 Hz, H3), 2.11 (1H, dd, J = 13.7, 5.8 Hz, H6β), 1.71 (1H, 
ddd, J = 13.7, 10.2, 4.9 Hz, H6α), 1.18 (3H, d, J = 5.9 Hz, H9). δH (125 MHz, D2O): 77.8 
(C2), 75.7 (C7), 75.3 (C1), 73.3 (C3), 70.6 (C7a), 65.5 (C8), 64.2 (C5), 46.5 (C6), 22.8 
(C9). ESIMS m/z 204 [M+H]+. HRASAPMS found 204.1239, calcd for [C9H18NO4]+,  
204.1236 [M+H]+.  
Synthesis of hyacinthacine B4 (4), hyacinthacine B5 (5), and 7a-epi-hyacinthacine B3 
(33) 
Swern oxidation of 18 
(R)-3-((2R,3R,4R)-3,4-Bis(benzyloxy)-2-(benzyloxymethyl)-5-oxopyrrolidin-1-yl)butanoic 
acid (27). The title compound was prepared following the general method for the Swern 
oxidation using 21 (107 mg, 0.23 mmol), oxalyl chloride (195 µL, 2.27 mmol), DMSO 
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(322 µL, 4.54 mmol) and Et3N (1.26 mL, 9.08 mmol) in CH2Cl2 (17 mL). Purification by 
flash column chromatography (0:100 to 15:85 MeOH/CH2Cl2 as eluent) gave the title 
compound 27 (17 mg, 16%), a mixture of 3 unknown ketones (16 mg, 15%) and 
recovered 21 (41.4 mg, 39%), all as colorless oils. Rf 0.50 (10:90 MeOH/CH2Cl2). 
[α] 25D + 33.3 (c 0.33, CHCl3). IR υmax (cm
-1): 3062, 3030, 2931, 2867, 1696, 1495, 1452, 
1354, 1307, 1102, 1026, 774, 657. δH (500 MHz, CDCl3): 7.36 - 7.26 (13H, m), 7.16 (2H, 
d, J = 7.5 Hz), 4.87 (1H, d, J = 12.2 Hz), 4.71 (1H, d, J = 12.2 Hz), 4.63 (1H, d, J = 12.2 
Hz), 4.54 (1H, d, J = 12.2 Hz), 4.43 (1H, d, J = 11.7 Hz), 4.39 (1H, d, J = 11.7 Hz), 4.22 
(1H, d, J = 5.4 Hz), 4.05 - 3.98 (1H, m), 3.94 (1H, d, J = 5.4 Hz), 3.63 (1H, s (br)), 3.48 
(1H, dd, J = 10.2, 4.4 Hz), 3.47 (1H, dd, J = 10.2, 3.4 Hz), 2.96 (1H, dd, J = 16.1, 7.3 Hz), 
2.76 (1H, dd, J = 16.1, 6.8 Hz), 1.31 (3H, d, J = 2.9 Hz). δC (75 MHz, CDCl3): 174.9 
(CO), 172.6 (CO), 137.8 (2 x ArC), 137.5 (ArC), 128.6 (2 x ArCH), 128.5 (4 x ArCH), 
128.3 (2 x ArCH), 128.1 (2 x ArCH), 128.0 (2 x ArCH), 127.9 (ArCH), 127.7 (2 x 
ArCH), 75.9 (CH), 75.7 (CH), 73.4 (CH2), 72.7 (CH2), 71.9 (CH2), 68.5 (CH2), 62.1 (CH), 
47.4 (CH), 38.3 (CH2), 18.2 (Me). ESIMS m/z 526 (100%) [M+Na]+. HRASAPMS found 
504.2407, calcd for C30H34NO6, 504.2386 [M+H]+. 








(benzyloxymethyl)-3-methylhexahydro-1H-pyrrolizin-1-ol (30), and (3R,4R,5R)-3,4-
Bis(benzyloxy)-5-(benzyloxymethyl)-1-((R)-4-hydroxybutan-2-yl)pyrrolidin-2-one (31).  
Step 1: Following the general method for the Swern oxidation using DMSO (778 µL, 
10.96 mmol), oxalyl chloride (470 µL, 5.48 mmol), alcohol 18 (259 mg, 0.55 mmol), 
anhydrous CH2Cl2 (30 mL) and Et3N (3.04 mL, 21.92 mmol) at -78 oC a yellow oil was 
obtained which was used without further purification in the next reaction with L-
Selectride®.  
Step 2: Following the general method for reduction of a ketone to a secondary alcohol 
with L-selectride® the above Swern oxidation crude product in THF (20 mL) was treated 
with L-selectride® (1.0 M solution in THF, 2.19 mL, 2.19 mmol). Purification by flash 
column chromatography (2:98 to 15:85 MeOH/CH2Cl2 as eluent) gave compounds 28 
(11.7 mg, 4%), 29 (18.0 mg, 7%), 30 (20.5 mg, 7%) and 31 (17.8 mg, 8%) and recovered 
21 (18.1 mg, 7%).  
28: Rf  0.44 (10:90 MeOH/CH2Cl2). [α] 25D
 + 11.5 (c 0.33, CHCl3). IR υmax (cm-1): 3350, 
3030, 2919, 2868, 1690, 1452, 1363, 1097, 1026, 735, 644. δH (500 MHz, CDCl3): 7.34 - 
7.26 (15H, m), 4.81 (1H, d, J = 11.7 Hz), 4.61 (1H, d, J = 11.7 Hz), 4.59 (1H, d,  J = 11.7 
Hz), 4.55 (1H, d, J = 11.7 Hz), 4.54 (2H, s), 4.44 - 4.39 (1H, m), 4.34 (1H, dd, J = 5.4, 
4.9 Hz), 4.04 (1H, dd, J = 5.8, 4.4 Hz), 3.83 (1H, s (br)), 3.68 - 3.66 (1H, m), 3.60 - 3.55 
(2H, m), 3.46 - 3.43 (1H, m), 2.17 (1H, dt, J = 12.2, 6.3 Hz), 1.69 - 1.78 (1H, m), 1.28 
(3H, d, J = 6.8 Hz). δC (75 MHz, CDCl3): 138.1 (ArC), 137.5 (ArC), 137.3 (ArC), 128.8 
(4 x ArCH), 128.6 (2 x ArCH), 128.4 (2 x ArCH), 128.3 (2 x ArCH), 128.2 (2 x ArCH), 
128.1 (2 x ArCH), 128.0 (ArCH), 81.4 (C2), 78.3 (C1), 73.6 (2 x CH2), 73.0 (CH2), 71.4 
(C7, absent), 70.8 (C8, observed in HSQC), 68.3 (C7a), 61.2 (C3), 56.6 (C5, observed in 
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HSQC), 43.0 (C6), 16.8 (C9). ESIMS m/z 474 (100%) [M+H]+. HRASAPMS found 
474.2649, calcd for C30H36NO4, 474.2644 [M+H]+. 
29: Rf  0.32 (5:95 MeOH/CH2Cl2). [α] 25D - 62.5 (c 0.81, CHCl3). IR υmax (cm
-1): 3031, 
2926, 2870, 1717, 1452, 1361, 1267, 1097, 737, 697. δH (500 MHz, CDCl3): 7.32 - 7.24 
(13H, m), 7.20 (2H, d, J = 7.0 Hz), 4.55 (2H, d, J = 12.0 Hz), 4.45 (1H, J = 12.0 Hz), 
4.43 (2H, d, J = 12.0 Hz), 4.34 (1H, J = 12.0 Hz), 4.15 (1H, s), 3.99 (1H, s), 3.71 - 3.67 
(2H, m), 3.54 - 3.48 (3H, m), 2.25 - 2.13 (2H, m), 1.36 (3H, d, J = 6 .7 Hz). δC (125 MHz, 
CDCl3): 218.0 (C7), 138.4 (ArC), 137.6 (2 x ArC), 128.7 (2 x ArCH), 128.6 (2 x ArCH), 
128.5 (2 x ArCH), 128.0 (2 x ArCH), 127.8 (4 x ArCH), 127.6 (3 x ArCH), 84.0 (C1), 
83.0 (C2), 76.4 (C7a), 73.3 (CH2), 73.0 (C8), 71.6 (CH2), 70.9 (CH2), 62.7 (C3), 54.5 
(C5), 43.1 (C6), 17.2 (C9). ESIMS m/z 472 (100%) [M+H]+. HRASAPMS found 
472.2469, calcd for C30H34NO4, 472.2488 [M+H]+. 
30: Rf  0.69 (20:80 MeOH/CH2Cl2). [α] 25D + 30.3 (c 0.12, CHCl3). IR υmax (cm
-1): 3271, 
3030, 2919, 2861, 1454, 1364, 1206, 1102, 1035, 665, 645. δH (500 MHz, CDCl3): 7.35 - 
7.18 (15H, m), 4.71 (1H, d, J = 12.7 Hz), 4.68 (1H, d, J = 12.7 Hz), 4.56 (2H, s), 4.45 
(1H, d, J = 11.7 Hz), 4.39(1H, d, J = 11.7 Hz), 4.20 (1H, dd, J = 7.3, 4.9 Hz), 4.07 - 4.04 
(2H, m), 3.85 (1H, s (br)), 3.71 (1H, dd, J = 10.5, 2.9 Hz), 3.48 (1H, s (br)), 3.33 (1H, dd, 
J = 10.5, 2.0 Hz), 3.24 - 3.20 (1H, m), 2.05 (1H, dd, J = 12.7, 5.4 Hz), 1.72 (1H, td, J = 
12.7, 3.4 Hz), 1.30 (3H, d, J = 5.8 Hz). δC (125 MHz, CDCl3): 138.8 (ArC), 136.9 (2 x 
ArC), 128.7 (2 x ArCH), 128.5 (2 x ArCH), 128.3 (2 x ArCH), 128.1 (2 x ArCH), 127.9 
(2 x ArCH), 127.7 (2 x ArCH), 84.1 (C7, observed in HMBC), 75.6 (C1, br), 73.7 (CH2), 
73.3 (C2, br), 72.2 (CH2), 71.8 (CH2), 71.6 (C7a, br), 68.0 (C8, observed in HMBC), 62.0 
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(C3), 50.2 (C5, observed in HMBC), 46.6 (C6, br), 29.8 (C9). ESIMS m/z 474 (100%) 
[M+H]+. HRASAPMS found 474.2635, calcd for C30H36NO4, 474.2644 [M+H]+. 
31: Rf  0.54 (5:95 MeOH/CH2Cl2). [α] 25D + 77.2 (c 0.95, CHCl3). IR υmax (cm
-1): 3400, 
2929, 2866, 1645, 1452, 1359, 1259, 1101, 1025, 697. δH (500 MHz, CDCl3): 7.38 - 7.16 
(15H, m), 4.93 (1H, d, J = 12.2 Hz), 4.76 (1H, d, J = 12.2 Hz), 4.70 (1H, d, J = 12.2 Hz), 
4.53 (1H, d, J = 12.2 Hz), 4.42 (2H, s), 4.36 (1H, d, J = 4.9 Hz), 4.33 - 4.26 (1H, m), 4.01 
(1H, d, J = 4.9 Hz), 3.57 (2H, s (br)), 3.52 (1H, s (br)), 3.48 (1H, dd, J = 10.2, 2.9 Hz), 
3.44 (1H, dd, J = 10.2, 4.9 Hz), 1.74 - 1.70 (2H, m), 1.17 (1H, d, J = 7.3 Hz). δC (125 
MHz, CDCl3): 173.8 (CO), 137.9 (2 x ArC), 137.3 (ArC), 128.7 (2 x ArCH), 128.5 (2 x 
ArCH), 128.4 (2 x ArCH), 128.2 (2 x ArCH), 128.1 (ArCH), 128.0 (2 x ArCH), 127.9 
(ArCH), 127.8 (3 x ArCH),  76.9 (CH), 76.2 (CH), 73.6 (CH2), 72.7 (CH2), 72.3 (CH2), 
69.1 (CH2), 59.9 (CH), 58.6 (CH2), 45.1 (CH), 36.1 (CH2), 19.8 (Me). ESIMS m/z 512 
(100%) [M+Na]+. HRESIMS found 512.2413, calcd for C30H35NO5Na, 512.2413 
[M+Na]+. 
(1S,3R,5R,6R,7R,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-ol (32): Following the general method for the reduction of a ketone to a 
secondary alcohol with L-selectride®,  the ketone 29 (16 mg, 0.034 mmol) in THF (6 mL) 
was treated with L-selectride® (1.0 M solution in THF, 136 µL, 0.14 mmol). Purification 
by flash column chromatography (2:98 to 10:90 MeOH/CH2Cl2 as eluent) gave the title 
compound (9 mg, 58%) as a colorless oil. Rf  0.54 (10:90 MeOH/CH2Cl2). [α] 25D - 16.5 (c 
0.47, CHCl3). IR υmax (cm-1): 3369, 3063, 3032, 2927, 2865, 1690, 1454, 1365, 1207, 
1099, 1028, 740, 670. δH (500 MHz, CDCl3): 7.31 - 7.24 (15H, m), 4.61 (1H, d, J = 11.6 
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Hz), 4.56 (1H, d, J = 11.7 Hz), 4.55 (1H, d, J = 11.7 Hz), 4.50 (1H, d, J = 12.0 Hz), 4.46 
(1H, d, J = 11.6 Hz), 4.44 (1H, d, J = 12.0 Hz), 4.28 (1H, s (br)), 4.18 (1H, s), 4.09 (1H, 
s), 3.70 (1H, br), 3.50 (1H, s (br)), 3.45 (1H, dd, J = 9.1, 8.8 Hz), 3.38 (1H, s (br)), 3.20 
(1H, s (br)), 2.24 (1H, dt, J = 12.5, 5.9 Hz), 1.37 (1H, dd, J =12.5, 10.5 Hz), 1.24 (3H, d, 
J = 6.6 Hz). δC (125 MHz, CDCl3): 138.4 (ArC), 138.2 (ArC), 137.2 (ArC), 128.8 (2 x 
ArCH), 128.6 (4 x ArCH), 128.3 (3 x ArCH), 128.0 (2 x ArCH), 127.9 (3 x ArCH), 127.8 
(ArCH), 85.6 (C2), 82.6 (C1, br), 73.7 (C7), 73.5 (C7a, observed in the HSQC), 73.4 
(CH2), 72.8 (C8, observed in the HSBC), 71.8 (2 x CH2), 62.5 (C3, br), 54.6 (C5, br), 
42.9 (C6, br), 17.0 (C9, br). ESIMS m/z 474 (100%) [M+H]+. HRASAPMS found 
474.2652, calcd for C30H36NO4, 474.2644 [M+H]+. 
(1S,2R,3R,5R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-1,2,7-triol 
(hyacinthacine B5) (5). Following the general method for hydrogenolysis of benzyl ethers, 
the alcohol 28 (11.7 mg, 0.03 mmol) was treated with PdCl2 (6.6 mg, 0.04 mmol) and 
MeOH (2 mL) at rt (19 oC) for 3 h. The title compound (1.5 mg, 21%) was obtained as a 
colorless film. [α] 25D
 - 21.6 (c 0.08, H2O). [Lit.3c [α]D - 25.4 (c 0.26, H2O), temperature 
not reported]. IR υmax (cm-1): 3299, 2953, 1587, 1555, 1399, 1044, 839, 760, 692. δH (500 
MHz, D2O): 4.55 (1H, td, J = 7.1, 6.8 Hz, H7), 4.34 (1H, dd, J = 4.4, 3.9 Hz, H1), 4.04 
(1H, dd, J = 7.3, 4.4 Hz, H2), 3.69 (1H, dd, J = 11.2, 4.4 Hz, H8A), 3.65 (1H, dd, J = 11.2, 
5.4 Hz, H8B), 3.52 (1H, dd, J = 6.9, 4.4 Hz, H7a), 3.39 (1H, td, J = 6.1, 5.3 Hz, H3), 3.34 
- 3.30 (1H, m, H5), 2.19 (1H, dt, J = 12.7, 6.3 Hz, H6β), 1.79 (1H, dt, J = 12.7, 8.3 Hz, 
H6α), 1.29 (3H, d, J = 6.8 Hz, H9). δC (75 MHz, D2O): 77.6 (C2), 75.6 (C7), 75.1 (C1), 
69.7 (C7a), 66.0 (C8), 65.3 (C3), 57.7 (C5), 44.3 (C6), 18.1 (C9). ESIMS m/z 204 (100%) 




(hyacinthacine B4) (4). Following the general method for hydrogenolysis of benzyl ethers, 
the alcohol 32 (8.4 mg, 0.018 mmol) was treated with PdCl2 (4.8 mg, 0.027 mmol) and 
MeOH (1.4 mL) at rt (22 oC) for 3 h. The title compound (3.6 mg, 100%) was obtained as 
a colorless film. [α] 25D - 7.7 
 (c 0.18, H2O). [Lit.3c [α]D - 6.7 (c 1.19, H2O), temperature 
not reported]. IR υmax (cm-1): 3291, 2930, 2882, 1637, 1592, 1384, 1343, 1137, 1064, 612. 
δH (500 MHz, D2O): 4.44 (1H, td, J = 6.4, 5.7 Hz, H7), 4.16 (1H, dd, J = 7.8, 7.3 Hz, H1), 
3.97 (1H, dd, J = 7.8, 7.0 Hz, H2), 3.69 (2H, d, J = 5.4 Hz, H8), 3.30 (1H, dd, J = 7.3, 6.8 
Hz, H7a), 3.28 - 3.24 (1H, m, H5), 3.14 (1H, dt, J = 7.8, 5.4 Hz, H3), 2.14 (1H, dt, J = 
13.2, 5.7 Hz, H6β), 1.71 (1H, ddd, J = 13.2, 7.3, 6.4 Hz, H6α), 1.26 (3H, d, J = 7.3 Hz, 
H9). δC (125 MHz, D2O): 82.0 (C2), 77.1 (C1), 73.1 (C7), 72.9 (C7a), 66.0 (C8), 64.5 
(C3), 57.0 (C5), 42.7 (C6), 19.0 (C9). ESIMS m/z 204 (100%) [M+H]+. HRASAPMS 
found 204.1246, calcd for C9H18NO4, 204.1236 [M+H]+. 
 (1S,2R,3R,5R,7R,7aS)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-1,2,7-triol 
(7a-epi-hyacinthacine B3) (33). Following the general method for hydrogenolysis of 
benzyl ethers, the alcohol 30 (2.3 mg, 0.005 mmol) was treated with PdCl2 (1.3 mg, 0.008 
mmol), and MeOH (0.5 mL) at rt (24 oC). The title compound (1.0 mg, 100%) was 
obtained as a colorless film. [α] 25D - 5.3 (c 0.11, H2O). IR υmax (cm
-1): 3294, 2967, 1649, 
1552, 1405, 1083, 1044. δH (500 MHz, D2O): 4.38 (1H, t, J = 3.9 Hz, H7), 4.26 (1H, dd, J 
=  4.4, 3.9 Hz, H1), 4.08 (1H, dd, J =  7.3, 4.9 Hz, H2), 3.97 (1H, dd, J = 12.7, 6.8 Hz, 
H8A), 3.89 (1H, dd, J = 12.7, 3.9 Hz, H8B), 3.59 (1H, dd, J = 4.4, 3.9 Hz, H7a), 3.51, (1H, 
ddd, J = 5.9, 4.4, 3.9 Hz, H5), 3.23 (1H, ddd, J = 6.8, 4.9, 3.9 Hz, H3), 2.05 (1H, ddd, J = 
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13.2, 4.4, 3.9 Hz, H6β), 1.71 (1H, ddd, J = 13.2, 11.2, 4.4 Hz, H6α), 1.22 (3H, d, J = 5.9 
Hz, H9). δC (125 MHz, D2O): 77.5 (C7a), 76.4 (C2), 72.1 (C7), 72.0 (C1), 66.8 (C3), 61.4 
(C8), 55.2 (C5), 46.3 (C6), 22.0 (C9). ESIMS m/z 204 (100%) [M+H]+. HRASAPMS 
found 204.1234, calcd for C9H18NO4, 204.1236 [M+H]+. 
(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-yl 4-nitrobenzoate (36). Following the general method for the Mitsunobu 
reaction, the alcohol 21 (144 µg, 0.30 mmol) was treated with triphenylphosphine (354 
mg, 1.35 mmol), p-nitrobenzoic acid (226 mg, 1.35 mmol) and diisopropyl 
azodicarboxylate (266 µL, 3.96 mmol) in toluene (3 mL) at 80 oC for 2 d. Purification by 
flash column chromatography (20:70 to 50:50 EtOAc/petrol as eluent) gave the title 
compound (ca 70% pure) (40 mg) as a yellow film and recovered 21 (45.5 mg, 32%) was 
also isolated. Rf  0.60 (5:95 MeOH/CH2Cl2). IR υmax (cm-1): 2921, 2854, 1722, 1527, 
1347, 1273, 1103, 1027, 736, 697. δH (500 MHz, CDCl3): 8.28 (2H, d, J = 8.8 Hz), 8.16 
(2H, d, J = 8.8 Hz), 7.37 - 7.22 (15H, m), 5.77 (1H, dt, J = 7.3, 4.1 Hz), 4.75 (1H, d, J = 
11.7 Hz), 4.64 - 4.47 (5H, m), 4.19 (1H, dd, J = 5.3, 4.1 Hz), 3.93 (1H, s (br)), 3.78 (1H, 
dd, J = 5.3, 3.2 Hz), 3.68 - 3.60 (1H, m), 3.42 (3H, s (br)), 2.01 (2H, m), 1.27 (3H, d, J = 
6.2 Hz). δC (125 MHz): 164.4 (CO), 150.6 (ArC), 138.3 (2 x ArC), 138.2 (ArC), 135.7 
(ArC), 130.8 (2 x ArCH), 128.7 (2 x ArCH), 128.5 (4 x ArCH), 127.9 (3 x ArCH), 127.8 
(5 x ArCH), 127.7 (2 x ArCH), 123.6 (ArCH), 81.4 (C2), 76.9 (C1), 76.1 (C7, br), 73.5 
(CH2), 73.4 (CH2), 72.6 (CH2), 72.4 (C8), 60.1 (C3), 56.7 (C5), 39.8 (C6), 22.1 (C1). 





pyrrolizin-1-yl methanesulfonate (37). Following the general method for mesylation-
cyclization, the alcohol 21 (16.8 mg, 0.034 mmol) was treated with triethylamine (81 µL, 
0.58 mmol), methanesulfonyl chloride (184 µL, 2.38 mmol) and CH2Cl2 (1.5 mL) at rt 
for 24 h. Purification by flash column chromatography (0:100 to 5:95 MeOH/CH2Cl2 as 
eluent) gave the title compound (16.5 mg, 87%) as a colorless oil. Rf  0.67 (5:95 
MeOH/CH2Cl2). [α] 25D  - 10.5 (c 0.16, CHCl3). IR υmax (cm
-1): 3063, 3030, 2929, 2866, 
1453, 1351, 1174, 1116, 1026, 935, 895, 697. δH (500 MHz, CDCl3): 7.35 - 7.25 (15H, 
m), 5.50 - 5.49 (1H, m), 4.59 - 4.44 (6H, m), 4.22 (1H, dd, J = 5.9, 4.9 Hz), 3.89 (1H, s 
(br)), 3.66 - 3.64 (1H, m), 3.56 - 3.49 (1H, m), 3.33 (1H, dd, J = 8.5, 4.4 Hz), 3.28 - 3.25 
(1H, m), 3.20 (1H, dd, J = 8.5, 7.8 Hz), 2.81 (3H, s), 2.06 (1H, dd, J = 13.7, 4.9 Hz), 1.93 
- 1.86 (1H, m), 1.19 (3H, d, J = 6.8 Hz). δC (75 MHz, CDCl3): 138.3 (ArC), 137.9 (2 x 
ArC), 132.2 (2 x ArCH), 128.5 (ArCH), 128.2 (4 x ArCH), 128.0 (2 x ArCH), 127.9 (4 x 
ArCH), 127.8 (2 x ArCH), 83.3 (C7), 79.2 (C2), 77.2 (C1), 73.6 (CH2), 73.4 (C7a), 72.9 
(CH2), 72.4 (C8), 71.6 (CH2), 60.6 (C3), 56.8 (C5), 39.9 (C6), 37.7 (Me), 15.5 (C9). 
ESIMS m/z 552 (100%) [M+H]+. HRESIMS found 552.2418, calcd for C31H38NO6S, 
552.2420 [M+H]+. 
(1R,3R,5R,6R,7S,7aR)-6,7-Bis(benzyloxy)-5-(benzyloxymethyl)-3-methylhexahydro-1H-
pyrrolizin-1-yl benzoate (38). A solution of the mesylate 36 (31 mg, 0.06 mmol) in 
DMSO (6 mL) was stirred at rt for 5 min and then cesium benzoate (26 mg, 0.11 mmol) 
was added. The reaction mixture was stirred at 70 oC for 2 d. After the reaction mixture 
had cooled to rt, a satd aqu solution of Na2CO3 (5 mL) was added and then extracted with 
Et2O (3 x 20 mL), dried (MgSO4) and concentrated in vacuo to give a light brown film. 
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Purification by flash column chromatography (increasing polarity from 5:95 to 20:80 of 
EtOAc/CH2Cl2 as eluent) gave the title compound (14 mg, 42%) as a colorless film. Rf  
0.20 (2:98 MeOH/CH2Cl2). [α] 25D - 18.7 (c 0.28, CHCl3). IR υmax (cm
-1): 3063, 3031, 
2924, 2862, 1715, 1452, 1358, 1273, 1111, 1025, 736, 696. δH (500 MHz, CDCl3): 8.01 
(2H, d, J = 7.8 Hz), 7.52 (1H, t, J = 7.3 Hz), 7.42 (2H, dd, J = 7.8, 7.3 Hz), 7.33 - 7.22 
(15H, m), 5.75 - 5.72 (1H, m), 4.74 (1H, d, J = 11.7 Hz), 4.67 (1H, d, J = 11.7 Hz), 4.62 
(1H, d, J = 11.7 Hz), 4.56 (1H, d, J = 12.2 Hz), 4.51 (1H, d, J = 11.7 Hz), 4.49 (1H, d, J = 
12.2 Hz), 4.18 (1H, dd, J = 4.9, 3.9 Hz), 3.92 (1H, t, J = 3.9 Hz), 3.78 (1H, s (br)), 3.66 - 
3.62 (1H, m), 3.43 (3H, s (br)), 2.02 - 2.00 (2H, m), 1.22 (3H, d, J = 6.8 Hz). δC (125 
MHz, CDCl3): 166.4 (CO), 138.6 (2 x ArC), 138.4 (ArC), 133.0 (2 x ArCH), 130.7 (ArC), 
129.7 (2 x ArCH), 128.4 (4 x ArCH), 127.9 (2 x ArCH), 127.8 (4 x ArCH), 127.7 (2 x 
ArCH), 127.6 (2 x ArCH), 81.7 (C2), 76.9 (C1), 75.6 (C7), 73.5 (CH2), 73.3 (CH2), 72.5 
(C7a and CH2), 72.2 (C8), 59.9 (C3), 56.4 (C5), 39.9 (C6), 16.2 (C9). ESIMS m/z 578 
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